Reuters logo
BRIEF-Roche says data show superiority of Ocrevus compared to Rebif
October 27, 2017 / 5:08 AM / a month ago

BRIEF-Roche says data show superiority of Ocrevus compared to Rebif

Oct 27 (Reuters) - Roche Holding AG

* Data show superiority of Ocrevus compared to Rebif (interferon beta-1a) in significantly reducing disability progression independent of relapse activity (pira) in people with relapsing multiple sclerosis (rms) Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below